Overview

Obesity is a highly heritable multifactorial disease that is regulated by genetics, individual behavior, environment, and endocrinology. Among them, genetic variations influence the obesity phenotype through epigenetic regulation interacting with environmental factors. Integrated genetic and epigenetic analyses help predict the risk of developing obesity and facilitate research into personalized prevention strategies. Protheragen is at the forefront of obesity and offers a one-stop genetic and epigenetic sequencing-based obesity risk analysis service, drawing on its extensive experience and expertise. Our ultimate goal is to help our clients make breakthroughs in the field of obesity research through innovative technologies and tailored experimental protocols.

Exploring Genetic and Epigenetic Changes in Obesity at Protheragen

Advanced instruments, algorithms, and software empower us to analyze large volumes of data and provide valuable insights and reliable support for the genetic basis of obesity and obesity risk analysis. Specific services include the following:

• Whole Genome Sequencing (WGS)

  WGS provides a comprehensive view of the entire genome of the sample and is used to detect single nucleotide site variants (SNPs), insertions/deletions, copy number changes, and structural variants. We use WGS to compare the sample's genes with the original genes, analyze obesity-related mutations, and copy number mutation sites. This provides clues for a deeper understanding of the genetic basis of obesity and the prediction of obesity risk.

• Whole-exome Sequencing (WES)

  WES is an analytical method that captures and enriches DNA from exonic regions of the whole genome for high-throughput sequencing. The technology only detects DNA in the exome region, making the target region more specific and the data more accurate. Meanwhile, high-depth sequencing identifies mutations that are not identified by whole genome sequencing, such as SNPs and other types of variants, which is important for the identification of obesity-related genes, genetic variation analysis, and obesity risk analysis. We have a complete and optimized WES process to efficiently capture, enrich, and sequence DNA from exome regions of various samples.

• Epigenome-wide Association Studies (EWAS)

  Epigenetic changes, especially altered DNA methylation patterns, may be intermediate biomarkers of obesity and may provide valuable information on underlying biological mechanisms. EWAS has demonstrated a link between DNA methylation, and obesity. We perform epigenetic sequencing and use EWAS to analyze the differences in epigenetic modifications between samples and to screen for epigenetic markers associated with obesity to further decipher the molecular mechanisms of obesity.

• Functional Annotation and Pathway Analysis

  We use advanced algorithms and software to perform functional annotation and pathway analysis of genes. By assigning genes to different pathways and functional classifications, we understand their impact on obesity, thus providing reliable information for obesity gene identification and obesity risk analysis.

• Analysis of Gene-environment Interactions

  The study has found that obesity susceptibility genes interacted with various lifestyles and environments. Understanding the interactions between genes and environmental components helps to select more specific and effective obesity prevention measures based on specific genetic composition. We study gene-environment interactions and analyze their relationship with obesity-related traits. In addition to this, we are helping to Predict Obesity and detailed risk by elucidating gene-environment interactions with broader environmental factors. This personalized prevention is likely to be more effective than generic prevention approaches.

  We also offer more detailed identification of obesity-related genes and various analytical services for obesity risk prediction as described below:

  WGS-based Obesity-Related Gene Identification Service

  WES-based Obesity-Related Gene Identification Service

  EWAS-based Obesity-Related Epigenetic Modification Analysis Service

  Multi-Omics Integration Analysis Service for Obesity Risk Prediction

  Functional Annotation and Pathway Analysis Service for Obesity Risk Prediction

  Gene-Environment Interactions Analysis Service for Obesity Risk Prediction

  Individual Genetic Profiling Service for Obesity Risk Prediction

Full Range of Anti-Obesity Therapy Development Services

We also provide a one-stop service for anti-obesity therapy development, from target screening, and anti-obesity therapy design to preclinical studies.

• Target screening

  We focus on the exploration and discovery of established and emerging molecular targets for anti-obesity therapies, as well as insightful research on their relationship to obesity.

  • Hormones and Peptides
  • Receptors
  • Enzymes

  • Metabolic Regulators
  • Signaling Molecules

• Anti-obesity therapy research

  There are a variety of anti-obesity therapies being developed. After understanding our client's research needs, we screen for appropriate targets and design tailored therapeutic strategies. Our team has extensive experimental experience in therapeutic development and provides innovative solutions.

  Small Molecule Drug Gene Therapy Cell Therapy Antibody Therapy Tissue Engineering Therapy Nanotherapy

• Preclinical studies of therapies

  We use multiple obesity models to analyze the efficacy and safety of anti-obesity therapies in a comprehensive and detailed manner.

  Pharmacodynamic Study of Anti-Obesity Therapeutics

  • Food/Water Intake Assessment
  • Quantitative Analysis of Body Fat Distribution
  • Energy Expenditure Monitoring
  • Measurement of Ectopic Fat Accumulation
  • Molecular Biomarker Analysis

  Pharmacokinetic Study of Anti-Obesity Therapeutics

  • DMPK Study of Anti-Obesity Drugs
  • ADME Study of Anti-Obesity Drugs

  Bioanalysis of Anti-Obesity Therapeutics

  • Biological Analysis of Macromolecular Drugs
  • Bioanalysis of Small Molecule Drugs

  Safety Assessment of Anti-Obesity Therapeutics

  • Safety Pharmacology Studies
  • Toxicology Studies

Workflow

We offer a complete experimental platform and a full range of services to help accelerate obesity risk analyses and other related research.

Applications

• Obesity risk prediction based on genetic and epigenetic sequencing provides valuable information for the study of personalized obesity intervention approaches.
• Genetic and epigenetic sequencing-based obesity risk prediction is essential for analyzing and studying the risk of developing obesity complications such as diabetes, some cancers, and others.
• Genetic and epigenetic sequencing data from obesity risk studies provide clues for researchers to better understand the molecular mechanisms of obesity and develop personalized treatments.

Advantages

• We offer a complete and customized obesity risk analysis program based on genetic and epigenetic sequencing to best meet our client's research needs.
• We have a well-established and standardized analysis process to ensure the reproducibility and uniformity of data related to obesity risk analysis projects based on genetic and epigenetic sequencing.
• Our professional and experienced service team will respond to any problems encountered by our clients in sequencing, identification of obesity-related genes, and analysis of epigenetic modifications promptly.

Publication Data

Frequently Asked Questions

What is the difference between EWAS and genome-wide association study (GWAS)?

They are both used to find loci associated with obesity at the genome-wide level. The difference between the two is that EWAS focuses on differences in epigenetic modifications and GWAS focuses on differences in SNPs.

What does epigenetic sequencing include?

• DNA hydroxymethylation sequencing
• Whole genome methylation sequencing
• RNA m6A methylation sequencing
• Others

Protheragen is the best partner for obesity research and offers a reliable obesity risk analysis service based on genetic and epigenetic sequencing. Please feel free to contact us if you have any questions in this regard. As a reliable helper, we will solve all your problems in obesity research.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.